In the last trading session, 3.15 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.17. With the company’s per share price at $0.72 changed hands at $0.0 or 0.35% during last session, the market valuation stood at $184.92M. ADAP’s last price was a discount, traded about -184.72% off its 52-week high of $2.05. The share price had its 52-week low at $0.43, which suggests the last value was 40.28% up since then. When we look at Adaptimmune Therapeutics Plc ADR’s average trading volume, we note the 10-day average is 2.41 million shares, with the 3-month average coming to 1.48 million.
Analysts gave the Adaptimmune Therapeutics Plc ADR (ADAP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.89. If we narrow down to specifics, the data shows that 1 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended ADAP as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Instantly ADAP was in green as seen at the end of in last trading. With action 9.31%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -8.80%, with the 5-day performance at 9.31% in the green. However, in the 30-day time frame, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) is -0.33% down. Looking at the short shares, we see there were 5.35 million shares sold at short interest cover period of 4.71 days.
The consensus price target for the stock as assigned by Wall Street analysts is 3, meaning bulls need an upside of 76.0% from its current market value. According to analyst projections, ADAP’s forecast low is 1 with 4 as the target high. To hit the forecast high, the stock’s price needs a -455.56% plunge from its current level, while the stock would need to soar -38.89% for it to hit the projected low.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
Data shows that the Adaptimmune Therapeutics Plc ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -32.41% over the past 6 months, a 77.78% in annual growth rate that is considerably higher than the industry average of 17.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.30%. The 2024 estimates are for Adaptimmune Therapeutics Plc ADR earnings to increase by 70.37%.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR is expected to release its next quarterly earnings report in January.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.38% of Adaptimmune Therapeutics Plc ADR shares while 60.27% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 60.49%. There are 60.27% institutions holding the Adaptimmune Therapeutics Plc ADR stock share, with MATRIX CAPITAL MANAGEMENT COMPANY, LP the top institutional holder. As of 2024-06-30, the company held 16.1135% of the shares, roughly 38.97 million ADAP shares worth $38.0 million.
ECOR1 CAPITAL, LLC holds the second largest percentage of outstanding shares, with 11.3299% or 27.4 million shares worth $26.72 million as of 2024-06-30.
